Antithetic hTERT Regulation by Androgens in Prostate Cancer Cells: hTERT Inhibition Is Mediated by the ING1 and ING2 Tumor Suppressors
Authors:
- Sophie BartschSBSophie Bartsch
- Kimia MirzakhaniKMKimia Mirzakhani
- Laura NeubertLaura Neubert
- Alexander StenzelASAlexander Stenzel
- Marzieh EhsaniMEMarzieh Ehsani
- Mohsen EsmaeiliMEMohsen Esmaeili
- Thanakorn PungsrinontTPThanakorn Pungsrinont
- Merve KacalMKMerve Kacal
- Seyed Mohammad Mahdi RasaSRSeyed Mohammad Mahdi Rasa
- Julia KallenbachJKJulia Kallenbach
- Divya DamodaranDDDivya Damodaran
- Federico RibaudoFRFederico Ribaudo
Open Access
Abstract
The human telomerase is a key factor during tumorigenesis in prostate cancer (PCa). The androgen receptor (AR) is a key drug target controlling PCa growth and regulates hTERT expression, but is described to either inhibit or to activate. Here, we reveal that androgens repress and activate hTERT expression in a concentration-dependent manner. Physiological low androgen levels activate, while, notably, supraphysiological androgen levels (SAL), used in bipolar androgen therapy (BAT), repress hTERT expression. We confirmed the SAL-mediated gene repression of hTERT in PCa cell lines, native human PCa samples derived from patients treated ex vivo, as well as in cancer spheroids derived from androgen-dependent or castration resistant PCa (CRPC) cells. Interestingly, chromatin immuno-precipitation (ChIP) combined with functional assays revealed a positive (pARE) and a negative androgen response element (nARE). The nARE was narrowed down to 63 bp in the hTERT core promoter region. AR and tumor suppressors, inhibitor of growth 1 and 2 (ING1 and ING2, respectively), are androgen-dependently recruited. Mechanistically, knockdown indicates that ING1 and ING2 mediate AR-regulated transrepression. Thus, our data suggest an oppositional, biphasic function of AR to control the hTERT expression, while the inhibition of hTERT by androgens is mediated by the AR co-repressors ING1 and ING2.Keywords
Funding Information
- Deutsche Krebshilfe (70113003)
This publication has 40 references indexed in Scilit:
- Telomerase at the intersection of cancer and agingTrends in Genetics, 2013
- Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 InhibitorsCancer Research, 2011
- Telomerase as an Important Target of Androgen Signaling Blockade for Prostate Cancer TreatmentMolecular Cancer Therapeutics, 2010
- Androgen Receptor Interacts with Telomeric Proteins in Prostate Cancer CellsJournal of Biological Chemistry, 2010
- An alternate pathway for androgen regulation of brain function: Activation of estrogen receptor beta by the metabolite of dihydrotestosterone, 5α-androstane-3β,17β-diolHormones and Behavior, 2008
- Wild‐type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer developmentThe FASEB Journal, 2007
- Phylogenetic Analysis of the ING Family of PHD Finger ProteinsMolecular Biology and Evolution, 2004
- Androgen ablation therapy for prostate carcinoma suppresses the immunoreactive telomerase subunit hTERTCancer, 2004
- In Vivo Regulation of hTERT Expression and Telomerase Activity by Androgen.Journal of Urology, 2003
- A new mathematical model for relative quantification in real-time RT-PCRNucleic Acids Research, 2001